ArticleTranslational oncology2026
Single-cell spatial transcriptomics identifies SERPINE1 as a vascular endothelial mediator of cisplatin resistance in head and neck squamous cell carcinoma.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCisplatin resistance remains a major obstacle in head and neck squamous cell carcinoma (HNSCC), yet the contribution of the vascular microenvironment and its variation across HPV statuses remains unclear.
methodsWe integrated single-cell RNA sequencing, spatial transcriptomics, and bioinformatics analyses to characterize cisplatin resistance-associated cellular states in HNSCC. Cisplatin resistance scoring, pseudotime analysis, transcriptional regulatory network analysis, and cell-cell communication analysis were used to identify resistant subpopulations. Spatial localization, survival analysis, immune infiltration assessment, and drug sensitivity prediction were further performed to evaluate key candidate genes.
resultsCisplatin resistance signals were preferentially enriched in tumor endothelial cells and were stronger in HPV-negative HNSCC. Endothelial cells with high resistance scores exhibited enhanced angiogenesis, extracellular matrix remodeling, hypoxia, and inflammatory programs. Multidimensional screening identified SERPINE1 as a key resistance-associated endothelial gene, showing significant upregulation and positive correlation with resistance scores. Single-cell and spatial transcriptomic analyses consistently demonstrated vascular-associated enrichment of SERPINE1, particularly in HPV-negative tumors. High SERPINE1 expression was associated with poor survival and an immunosuppressive tumor microenvironment. Drug sensitivity prediction suggested increased sensitivity of SERPINE1-high tumors to EGFR/SRC- and MAPK-pathway inhibitors, whereas no significant differences were observed for conventional cytotoxic agents.
conclusionSERPINE1 defines a tumor endothelial state associated with cisplatin resistance in HNSCC and may contribute to HPV-related differences in the vascular microenvironment, providing a potential basis for therapeutic stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.